Health Press Release – Newsletter for November 17, 2010

Ingenuity Systems and Sage Bionetworks Collaborate to Enable Predictive Disease Network Research

REDWOOD CITY, California, November 16, 2010 – Ingenuity(R) Systems, a leading provider of information solutions for
life science researchers, today announced a new collaboration with Sage
Bionetworks, a non-profit leader in predictive disease network research.
Under the collaboration, Sage will leverage IPA(R), Ingenuity's
industry-leading analysis software, and the Ingenuity(R) Knowledge Base of
structured biomedical Findings, to inform and enhance …. Original article  : Ingenuity Systems and Sage Bionetworks Collaborate to Enable Predictive Disease Network Research.

Edwards SAPIEN Transcatheter Heart Valve Demonstrates Substantial Improvement in Quality of Life in Inoperable Patients

IRVINE, California, November 16, 2010 – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the
science of heart valves and hemodynamic monitoring, announced that in
addition to the improved survival seen in inoperable aortic stenosis patients
treated with the Edwards SAPIEN transcatheter heart valve in The PARTNER
Trial, a newly released analysis of the same patients shows [..] Read the original article: here.

Elsevier Launches SciVerse Applications Beta…Enabling the Research Community to Deliver a New Era in Scientific Search and Discovery

Release of Content APIs Empowers Developers to Create New Tools to Accelerate Science and Offers Platform for Sharing with the Global Scientific Community

AMSTERDAM, November 16, 2010 – Elsevier (www.elsevier.com) , a world-leading publisher of
scientific, technical and medical information products and services, today
announced the launch of SciVerse Applications beta, a new module within the
SciVerse platform … Read more >>.

IntraLinks Enhances Study Management Offering; Expands its Suite of SaaS-based Solutions for Clinical Operations

IntraLinks for Study Management Provides Unparalleled Automation and Insight Into Document-Centric Processes Throughout the Entire Clinical Trial Lifecycle

NEW YORK, November 16, 2010 – IntraLinks, a leading provider of critical information exchange
solutions, today announced IntraLinks for Study Management, a secure, online
platform for managing and monitoring all communication and activity with
investigative sites and other outside parties … Original article on : IntraLinks Enhances Study Management Offering; Expands its Suite of SaaS-based Solutions for Clinical Operations.

GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI

Higher Cardiac Event Rates Seen in Patients with Higher Residual Platelet Reactivity, as Measured by the VerifyNow P2Y12 Test

SAN DIEGO, November 16, 2010 – Accumetrics, Inc., developer and marketer of the VerifyNow(R) System,
today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow
Assay-Impact On Thrombosis And Safety) Trial found that in patients with high
residual platelet … Read more : GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI.

Isotechnika Reports Development, Distribution and Licencing Agreement and Private Placement Financing With ILJIN Life Science co., Ltd., Amendment of Arrangements With Paladin Labs Inc., and Related Matters

EDMONTON, Canada, November 16, 2010 – Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Corporation")
today announced that it has entered into a Development, Distribution and
License Agreement (the "DDL") with ILJIN Life Science Co., Ltd ("ILJIN") for
the further clinical and commercial development of voclosporin for use in
transplant indications applicable to voclosporin. Under the DDL in exchange
for … Read the original article on Gaea Times at : Isotechnika Reports Development, Distribution and Licencing Agreement and Private Placement Financing With ILJIN Life Science co., Ltd., Amendment of Arrangements With Paladin Labs Inc., and Related Matters.

Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device

First Ever CE Approved Combination Device is an Attractive Treatment for Coronary Artery Diseases

HELMOND, The Netherlands, November 16, 2010 – Blue Medical today announced that the company received CE Mark approval
for Blue Medical science based Drug Eluting Balloon (DEB) and simultaneously
for Blue Medical's coronary CoCr stent mounted on a Drug Eluting Balloon
(CoCr Stent on …. Source article  : Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device.

SuperSonic Imagine Announces That Gordon Waldron Has Been Named Executive Vice President and CFO

AIX-EN-PROVENCE, France, November 16, 2010 – SuperSonic Imagine, the innovative ultrasound medical imaging company, is
pleased to announce Gordon Waldron has been named as Executive Vice President
and CFO. As a member of the board of directors, he will be responsible for
driving all of SuperSonic Imagine's key strategic and commercial partnerships
as well as overseeing the company's …. Source article  : SuperSonic Imagine Announces That Gordon Waldron Has Been Named Executive Vice President and CFO.